- Home
- VOXR vs CRDF Comparison
VOXR vs CRDF Comparison
Compare VOXR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- CRDF
- Stock Information
- Founded
- VOXR 2014
- CRDF 1999
- Country
- VOXR Canada
- CRDF United States
- Employees
- VOXR N/A
- CRDF N/A
- Industry
- VOXR Precious Metals
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VOXR Basic Materials
- CRDF Health Care
- Exchange
- VOXR Nasdaq
- CRDF Nasdaq
- Market Cap
- VOXR 126.5M
- CRDF 134.0M
- IPO Year
- VOXR N/A
- CRDF N/A
- Fundamental
- Price
- VOXR $2.74
- CRDF $2.52
- Analyst Decision
- VOXR
- CRDF Strong Buy
- Analyst Count
- VOXR 0
- CRDF 3
- Target Price
- VOXR N/A
- CRDF $9.33
- AVG Volume (30 Days)
- VOXR 277.5K
- CRDF 1.1M
- Earning Date
- VOXR 11-06-2024
- CRDF 11-07-2024
- Dividend Yield
- VOXR 1.75%
- CRDF N/A
- EPS Growth
- VOXR N/A
- CRDF N/A
- EPS
- VOXR N/A
- CRDF N/A
- Revenue
- VOXR $11,147,864.00
- CRDF $688,000.00
- Revenue This Year
- VOXR $1.91
- CRDF $15.00
- Revenue Next Year
- VOXR $8.94
- CRDF N/A
- P/E Ratio
- VOXR N/A
- CRDF N/A
- Revenue Growth
- VOXR N/A
- CRDF 49.57
- 52 Week Low
- VOXR $1.70
- CRDF $1.13
- 52 Week High
- VOXR $3.24
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- VOXR 43.42
- CRDF 40.24
- Support Level
- VOXR $2.43
- CRDF $2.85
- Resistance Level
- VOXR $2.79
- CRDF $2.70
- Average True Range (ATR)
- VOXR 0.11
- CRDF 0.41
- MACD
- VOXR -0.01
- CRDF -0.12
- Stochastic Oscillator
- VOXR 49.06
- CRDF 0.43
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of over 60 royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").